Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3 that can influence tumor growth, vascular angiogenesis and progression of cancer (the spread of tumors).
Pfizer has filed the application on the basis of Phase 3 results from AXIS 1032 trial.
Pfizer Oncology Business Unit president and general manager Garry Nicholson said this regulatory filing for their investigational therapy axitinib, as well as ongoing studies of their existing medications, underscore Pfizer’s commitment to patients with advanced RCC.